ATE213499T1 - Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose - Google Patents

Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose

Info

Publication number
ATE213499T1
ATE213499T1 AT95942842T AT95942842T ATE213499T1 AT E213499 T1 ATE213499 T1 AT E213499T1 AT 95942842 T AT95942842 T AT 95942842T AT 95942842 T AT95942842 T AT 95942842T AT E213499 T1 ATE213499 T1 AT E213499T1
Authority
AT
Austria
Prior art keywords
peptide analogues
multiple sclerosis
substitution
treatment
myelin protein
Prior art date
Application number
AT95942842T
Other languages
English (en)
Inventor
Nicholas Ling
Paul J Conlon
Amitabh Gaur
Lawrence Steinman
Original Assignee
Neurocrine Biosciences Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc, Univ Leland Stanford Junior filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ATE213499T1 publication Critical patent/ATE213499T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95942842T 1994-11-18 1995-11-16 Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose ATE213499T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34207894A 1994-11-18 1994-11-18
PCT/US1995/014402 WO1996016085A1 (en) 1994-11-18 1995-11-16 Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Publications (1)

Publication Number Publication Date
ATE213499T1 true ATE213499T1 (de) 2002-03-15

Family

ID=23340234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942842T ATE213499T1 (de) 1994-11-18 1995-11-16 Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose

Country Status (9)

Country Link
US (4) US6369033B1 (de)
EP (2) EP0792286B1 (de)
JP (1) JPH10509714A (de)
AT (1) ATE213499T1 (de)
AU (1) AU721898B2 (de)
CA (1) CA2205532A1 (de)
DE (1) DE69525544T2 (de)
MX (1) MX9703642A (de)
WO (1) WO1996016085A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
HU219306B (en) * 1992-04-09 2001-03-28 Autoimmune Inc T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
WO1996012737A2 (en) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1996016085A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
AU5360796A (en) * 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
AU1874997A (en) * 1996-02-15 1997-09-02 Pangenetics B.V. Molecules for the induction of immunological tolerance
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6541608B1 (en) * 1999-02-23 2003-04-01 Baylor College Of Medicine T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
WO2002077025A1 (en) * 2001-03-23 2002-10-03 John Matsoukas Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
AU2003258090B2 (en) * 2002-08-08 2010-07-22 Baylor College Of Medicine Isolation and identification of T cells
EP1874343A4 (de) 2005-04-19 2009-07-22 Lilly Co Eli Monovalente und polyvalente synthetische polysaccharid-antigene für immunologische interventionen bei krankheiten
WO2007131210A2 (en) * 2006-05-05 2007-11-15 Opexa Therapeutics T-cell vaccine
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
CN103102393B (zh) * 2013-01-30 2015-01-07 北京大学 一种多肽及其在制备抑郁症治疗药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
HUT61896A (en) * 1990-03-02 1993-03-29 Autoimmune Inc Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases
US6036957A (en) * 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
EP0587735B1 (de) * 1991-05-31 2000-01-26 Connetics Corporation T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
HU219306B (en) * 1992-04-09 2001-03-28 Autoimmune Inc T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
WO1995008572A1 (en) * 1993-09-22 1995-03-30 The Board Of Trustees For The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996016085A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Also Published As

Publication number Publication date
AU721898B2 (en) 2000-07-20
US20030114380A1 (en) 2003-06-19
DE69525544T2 (de) 2002-08-22
EP0792286A1 (de) 1997-09-03
US6740638B2 (en) 2004-05-25
JPH10509714A (ja) 1998-09-22
US20020058627A1 (en) 2002-05-16
US20040214775A1 (en) 2004-10-28
CA2205532A1 (en) 1996-05-30
EP1172376A1 (de) 2002-01-16
WO1996016085A1 (en) 1996-05-30
MX9703642A (es) 1998-11-29
AU4405796A (en) 1996-06-17
EP0792286B1 (de) 2002-02-20
US6369033B1 (en) 2002-04-09
US6489299B2 (en) 2002-12-03
DE69525544D1 (de) 2002-03-28

Similar Documents

Publication Publication Date Title
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE266043T1 (de) Peptidanaloge des menschlichen basischen myelinproteins
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
ATE230797T1 (de) Stabile produkte des bakterientötenden/durchlässigkeiterhöhenden proteins (pbi) und diese enthaltende arzneimittelzusammensetzungen
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
DE3852636D1 (de) Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
IL109403A0 (en) Oral drug delivery compositions and methods
FI860153A0 (fi) Oligopeptider, deras mellanprodukter och foerfarande foer deras framstaellning.
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
ATE377026T1 (de) Behandlung von fettleibigkeit
ATE60062T1 (de) Wachstumshormone freisetzende peptiden und methode fuer die behandlung von saeugetieren.
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
DE69430416D1 (de) Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
GR3001922T3 (en) Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration
DE69102069D1 (de) 5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen.
ATE92078T1 (de) Pharmakologisch aktive peptide.
DE3162674D1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
ATE27822T1 (de) Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties